Suppr超能文献

评估急性冠状动脉综合征患者对联合基本药物治疗的同时依从性及临床结局。一项基于人群的真实世界研究,采用基于群体的轨迹模型。

Assessing Concurrent Adherence to Combined Essential Medication and Clinical Outcomes in Patients With Acute Coronary Syndrome. A Population-Based, Real-World Study Using Group-Based Trajectory Models.

作者信息

Rodríguez-Bernal Clara L, Sánchez-Saez Francisco, Bejarano-Quisoboni Daniel, Hurtado Isabel, García-Sempere Anibal, Peiró Salvador, Sanfélix-Gimeno Gabriel

机构信息

Health Services Research Unit, The Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain.

Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), Valencia, Spain.

出版信息

Front Cardiovasc Med. 2022 May 25;9:863876. doi: 10.3389/fcvm.2022.863876. eCollection 2022.

Abstract

AIM

Adherence to multiple medications recommended for secondary prevention of cardiovascular conditions represents a challenge. We aimed to identify patterns of concurrent adherence to combined therapy and assess their impact on clinical outcomes in a cohort of patients with acute coronary syndrome (ACS).

METHODS

Population-based retrospective cohort of all patients discharged after hospitalization for ACS (2009-2011), prescribed ≥3 therapeutic groups within the first month. We assessed monthly concurrent adherence (≥24 days of medication out of 30) to ≥3 medications during the first year, and patterns were identified through group-based trajectory models. A composite clinical outcome during the second year was constructed. The association between adherence patterns and traditional refill adherence metrics [e.g., the proportion of days covered (PDC)], and outcomes were assessed through a multivariable Cox proportional hazards model.

RESULTS

Among 15,797 patients discharged alive, 12,057 (76.32%) initiated treatment with ≥3 therapeutic groups after discharge. We identified seven adherence trajectories to ≥3 medications: Adherent (52.94% of patients); Early Gap (6.64%); Middle Gap (5.67%); Late Decline (10.93%); Occasional Users (5.45%); Early Decline (8.79%); Non-Adherent (9.58%). Compared to the Adherent group, patients belonging to Early Gap (HR:1.30, 95%CI 1.07;1.60), Late decline (hazards ratio (HR): 1.31, 95% CI 1.1; 1.56), and Non-Adherent trajectories (HR: 1.36, 95% CI 1.14; 1.63) had a greater risk of adverse clinical outcomes, which was also different to the risk ascertained through concurrent PDC < 80 (HR: 1.13, 95% CI 1.01; 1.27).

CONCLUSION

Overall, seven adherence trajectories to ≥3 drugs were identified, with three distinct adherence patterns being at higher risk of adverse outcomes. The identification of patterns of concurrent adherence, a more comprehensive approach than traditional measurements, may be useful to target interventions to improve adherence to multiple medications.

摘要

目的

坚持服用推荐用于心血管疾病二级预防的多种药物是一项挑战。我们旨在确定联合治疗的同时坚持用药模式,并评估其对急性冠状动脉综合征(ACS)患者队列临床结局的影响。

方法

对所有因ACS住院后出院的患者(2009 - 2011年)进行基于人群的回顾性队列研究,这些患者在第一个月内被开具了≥3个治疗组的药物。我们评估了第一年中每月对≥3种药物的同时坚持用药情况(30天内用药≥24天),并通过基于组的轨迹模型确定模式。构建了第二年的综合临床结局。通过多变量Cox比例风险模型评估坚持用药模式与传统的再填充坚持用药指标[例如,覆盖天数比例(PDC)]之间的关联以及结局。

结果

在15,797名存活出院的患者中,12,057名(76.32%)出院后开始使用≥3个治疗组的药物治疗。我们确定了七种对≥3种药物的坚持用药轨迹:坚持用药(占患者的52.94%);早期间断(6.64%);中期间断(5.67%);后期下降(10.93%);偶尔用药者(5.45%);早期下降(8.79%);不坚持用药(9.58%)。与坚持用药组相比,属于早期间断组(风险比(HR):1.30,95%置信区间1.07;1.60)、后期下降组(HR:1.31,95%置信区间1.1;1.56)和不坚持用药轨迹组(HR:1.36,95%置信区间1.14;1.63)的患者发生不良临床结局的风险更高,这也与通过同时PDC < 80确定的风险不同(HR:1.13,95%置信区间1.01;1.27)。

结论

总体而言,确定了七种对≥3种药物的坚持用药轨迹,其中三种不同的坚持用药模式不良结局风险更高。确定同时坚持用药模式,这是一种比传统测量更全面的方法,可能有助于针对干预措施来提高对多种药物的坚持用药情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e46c/9174582/7a33494ca3d3/fcvm-09-863876-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验